ThromboGenics NV Announces Business Update and Half Year Re...(success fee. Corporate Update - ...)

    Corporate Update

    - As of 1 July 2009, ThromboGenics was promoted to the NEXT 150
      index on the Euronext stock exchange, reflecting the strong share price
      performance and progress that the Company has made. The NEXT 150 index
      comprises mid to large capitalization stocks on the Euronext exchange.
      The index consists of the 150 next largest stocks following the
      Euronext 100 index and includes stocks from the Amsterdam, Brussels,
      Lisbon and Paris exchanges of Euronext.

      The inclusion of the Company in the NEXT 150 index also
      follows the Company entering the VLAM-21 index earlier in the year,
      which is a capitalized-weighted index of the 21 most capitalized
      Flemish stocks that are traded on a stock exchange.

    - Cross-border merger of ThromboGenics NV and ThromboGenics Ltd
      finalized, leading to a streamlined legal structure and cost savings.

    - ThromboGenics has continued to strengthen its in-house
      expertise, following the strategic hires announced at the time of the
      Company's first quarter 2009 Business Update. In June, Dr. Clive Long
      joined ThromboGenics as Head of Pre-Clinical Program Management. Dr.
      Long joins from Schering-Plough, where he was Proof-of-Concept Leader
      and has 26 years experience working for large pharmaceutical companies
      in research and development.


    Financial Overview
    Revenue and Results

In the first half of 2009, ThromboGenics achieved total revenue of EUR3.6 million, nearly all of which came from its out-licensing activities. Within this amount, EUR3 million came from the first success fee from Roche based on the successful transfer and implementation of technology and process development for TB-403 production. In the same period of 2008, ThromboGenics had revenues of EUR30.3 million due to the upfront payment from Roche which resulted from the signi
'/>"/>